SCHEMBL5423262

SCHEMBL5423262

O=C(O)Nc1ccc(Oc2ccnc(-c3ncon3)n2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 6/20 0.42
KMT2A Q03164 2/20 0.38
KDR P35968 6/20 0.38
HTT P42858 3/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
LMNA P02545 2/20 0.38
HPGD P15428 1/20 0.38
BRAF P15056 1/20 0.37
MAPK14 Q16539 1/20 0.37
TNNI3K Q59H18 1/20 0.37
LOX P28300 2/20 0.37
LOXL2 Q9Y4K0 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
MEN1 O00255 1/20 0.36
USP2 O75604 1/20 0.36
ALDH1A1 P00352 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14447604 0.85 CYP17A1 (0.40) METKMT2AKDRBRAFMAPK14
SCHEMBL5441115 0.78 KDR (0.69) METKMT2AKDRBRAFMAPK14
SCHEMBL5339671 0.78 MEN1 (0.39) KMT2ARAB9ASMN1; SMN2MEN1ALDH1A1
SCHEMBL5319315 0.77 KDR (0.48) METKMT2AKDRHTTNPC1
SCHEMBL11712888 0.73 ADORA2A (0.41) KMT2AHTTNPC1RAB9ALMNA
SCHEMBL5317905 0.73 P2RX3 (0.45) METKMT2AKDRHTTNPC1
SCHEMBL5317782 0.72 KDR (0.44) METKMT2AKDRHTTNPC1
SCHEMBL24920836 0.69 PPARA (0.35) KMT2ANPC1LOXLOXL2MEN1
SCHEMBL31501270 0.68 PGR (0.62) HTTNPC1RAB9ALMNASMN1; SMN2
SCHEMBL9813659 0.67 ALDH1A1 (0.60) KMT2ANPC1RAB9ALMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 US disclosed
WO-2007076473-A2 SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES KALYPSYS, INC. (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155764-A1 NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES BRAF, ARAF, RAF1 MET 391/4885KMT2A 3676/4885KDR 555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.